16 hours ago 1

Gilead (GILD) Downplays FDA Decision to Pause HIV Combination Trial over Safety Concern

Abdul Rahman

Tue, Jun 17, 2025, 1:24 AM 1 min read

The FDA placed a hold on the HIV treatment trial of GS-1720 and GS-4182 on the identification of the safety signal of a decrease in CD4+ T-cells in trials. Gilead insists it is collaborating with authorities and working to resolve underlying issues. However, the FDA hold did not in any way affect multiple other HIV treatment combinations that the company is working on.

The combination is one of the several drugs that Gilead is working on to replace any revenue it could lose in case its bestselling HIV drug, Biktarvy, loses patent protection.

Gilead Sciences Inc. (NASDAQ:GILD) is a research-based biopharmaceutical company that discovers, develops, and commercializes innovative medicines in areas of unmet medical need. Each discovery and investigational drug candidate seeks to improve the care of patients living with life-threatening diseases worldwide.

While we acknowledge the potential of GILD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.